A Phase IV Trial of Cesamet™ Given With Standard Antiemetic Therapy for Chemotherapy-induced Nausea and Vomiting

This study has been terminated.
(Enrollment was too slow)
Sponsor:
Collaborator:
Valeant Pharmaceuticals International, Inc.
Information provided by:
Veeda Oncology
ClinicalTrials.gov Identifier:
NCT00418678
First received: January 3, 2007
Last updated: November 30, 2010
Last verified: August 2008
  Purpose

This is a Phase IV, open-label, sequential treatment study in patients who are receiving standard chemotherapy for non-small cell lung cancer, breast cancer, or colorectal cancer. (See Section 4.2.1 for eligible treatment regimens.) The study will take place during the first 2 cycles of chemotherapy.

Phase 1 of study:

Prior to the first dose of chemotherapy, patients will be instructed on how to complete their patient diary, which will include a Visual Analogue Scale (VAS) for nausea and a VAS for pain. In addition, the diary will include a section to list their current pain medications (see Sample Patient Diary in Appendix I). After being instructed, patients will complete the VAS for nausea and for pain, as well as listing their current pain medications. Patients will then receive chemotherapy on Day 1 of Cycle 1 in combination with the pre-defined standard serotonin antagonist/corticosteroid regimen.

Beginning on Day 2, the diary will be completed for 5 consecutive days (Days 2-6). Each day, patients will complete a diary entry pertaining to the preceding 24 hours. The entry will include the number and time of any emetic episodes, any antiemetic rescue medications used, VAS for nausea, and side effects of treatment. On the last day of the diary (Day 6), the entry will include the above daily parameters but will also include a VAS for pain. In addition, the patient will complete a diary entry pertaining to the 5-day study period that will include pain medications used. Patients will also complete the Functional Living Index - Cancer (FLIC) questionnaire (see Sample Function Living Index - Cancer questionnaire in Appendix II).

Patients who either have at least one vomiting episode or at least one report of significant nausea (VAS > 25 mm) during the first 5-day study period will be eligible for the second phase of the study.

Phase 2 of the study:

Patients in the second phase will receive a second cycle of the same chemotherapy. The antiemetic regimen for the second cycle will be the same serotonin antagonist/corticosteroid regimen as they received in Cycle 1, with the addition of Cesamet.

For Cycle 2 of treatment, patients will receive Cesamet 1 mg the night before chemotherapy is to be administered. On the day of chemotherapy (Day 1 of Cycle 2), Cesamet 2 mg will be given 1 to 3 hours before the chemotherapy is administered, in addition to the same serotonin antagonist/corticosteroid regimen as they received in Cycle 1. Patients will receive an additional dose of Cesamet 2 mg the evening of Day 1.

Patients will receive Cesamet 2 mg BID on Days 2-5. Patients will complete the same 5-day diary and FLIC questionnaire as they did in Cycle 1. Beneficial effects of Cesamet will be estimated by comparing the results of the second cycle to the results of the first cycle.

Patients will be evaluated for the first 2 cycles of chemotherapy only.


Condition Intervention Phase
Nausea and Vomiting
Drug: Cesamet
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase IV Trial of Cesamet™ Given With Standard Antiemetic Therapy for Chemotherapy-induced Nausea and Vomiting

Resource links provided by NLM:


Further study details as provided by Veeda Oncology:

Primary Outcome Measures:
  • To demonstrate incremental improvement with Cesamet in control of chemotherapy induced nausea and vomiting in patients who have failed to respond adequately to standard antiemetic regimens. [ Time Frame: unk ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To determine whether the addition of Cesamet to standard antiemetic regimens leads to incremental benefit in the secondary outcomes of: [ Time Frame: unk ] [ Designated as safety issue: No ]
  • The percent of patients with no emetic episodes, the percentage of patients with no nausea, the percentage of patients with no significant nausea [ Time Frame: unk ] [ Designated as safety issue: No ]
  • time to first emetic episode, decrease in pain over the 5 day study period, decrease in analgesic use over the 5 day study period,Improvement in global quality of life as compared to without cannabinoid use [ Time Frame: unk ] [ Designated as safety issue: No ]
  • the mean (or median) change in VAS score for nausea and pain [ Time Frame: unk ] [ Designated as safety issue: No ]

Enrollment: 16
Study Start Date: August 2006
Study Completion Date: December 2007
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Cesamet
    2 mg BID on Days 2-5.
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients must have signed an IRB-approved informed consent.
  2. Patients must be receiving moderately emetogenic chemotherapy for the first time with one of the following neoplasms/regimens:

    • Non-small cell lung cancer receiving paclitaxel and carboplatin
    • Breast cancer receiving cyclophosphamide and doxorubicin
    • Colorectal cancer receiving a FOLFOX regimen .
  3. Patients must have an ECOG Performance Status of 0 or 1 (see Appendix I).
  4. Patients must be >18 years of age.
  5. Patients must either be not of child bearing potential or have a negative serum pregnancy test within 7 days prior to registration. Patients are considered not of child bearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or they are postmenopausal for at least 12 months.
  6. Patients of childbearing potential must agree to use effective contraceptive measures during study treatment and for a reasonable time thereafter.
  7. Patients must have adequate bone marrow function based on requirements specified in prescribing guidelines for the chemotherapy regimen.
  8. Patients must have adequate renal and hepatic function based on requirements specified in prescribing guidelines for the chemotherapy regimen.

Exclusion Criteria:

  1. Patients with pre-existing nausea or vomiting.
  2. Patients with other potential causes of nausea or vomiting, including uncontrolled brain metastases, bowel obstruction, or gastrointestinal hemorrhage.
  3. Patients with prior adjuvant chemotherapy.
  4. Patients receiving concurrent radiotherapy to the brain or upper abdomen.
  5. Patients currently taking other antiemetics.
  6. Patients who have a history of hypersensitivity to a cannabinoid.
  7. Patients with a serious uncontrolled intercurrent medical illness, including serious infection.
  8. Patients with a current or previous psychiatric disorder (including manic depressive illness and schizophrenia), as the symptoms of these disease states may be unmasked by the use of cannabinoids. Cesamet should be used with caution in individuals receiving other psychoactive drugs.
  9. Patients with hypertension or heart disease, since Cesamet can elevate supine and standing heart rates and cause postural hypotension.
  10. Patients with a history of other malignancy within the last 5 years, which could affect the diagnosis or assessment of these study drugs.
  11. Any patient who is pregnant or lactating.
  12. Any patient who is unable to comply with the requirements of the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00418678

Locations
United States, Ohio
Veeda Oncology
Columbus, Ohio, United States, 43215
Sponsors and Collaborators
Veeda Oncology
Valeant Pharmaceuticals International, Inc.
Investigators
Principal Investigator: Ralph Boccia, M.D. Center for Cancer and Blood Disorders
  More Information

No publications provided

Responsible Party: Ralph Boccia, MD, CENTER FOR CANCER AND BLOOD DISORDERS
ClinicalTrials.gov Identifier: NCT00418678     History of Changes
Other Study ID Numbers: I-05-017
Study First Received: January 3, 2007
Last Updated: November 30, 2010
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Nausea
Vomiting
Signs and Symptoms, Digestive
Signs and Symptoms
Antiemetics
Nabilone
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Gastrointestinal Agents
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs

ClinicalTrials.gov processed this record on October 02, 2014